University of North Dakota   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Grand Forks ND United States (1883)

Organization Overview

First Clinical Trial
2000
NCT03558971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Center for Rural Health, University of North Dakota | Neuropsychiatric Research Institute and University of North Dakota | Neuropsychiatric Research Institute, University of North Dakota | University of North Dakota

Active Ingredients

Drugs in Phase 4 Trials (3)

amniotic epithelial cells (1 trial)

cortisone acetate (cortone) (1 trial)

topiramate (topamax) (1 trial)

Drugs in Phase 3 Trials (1)

duloxetine (Cymbalta) (1 trial)

Drugs in Phase 2 Trials (2)

celecoxib (celebrex) (1 trial)

vitamin d3 (2 trials)

Drugs in Other Trials (3)

icosapent ethyl (vascepa) (1 trial)

modanafil (1 trial)

olanzapine (zyprexa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Bulimia (Phase 4)

Bulimia Nervosa (Phase 4)

Collagen Diseases (Phase 4)

Diabetic Foot (Phase 4)

Foot Ulcer (Phase 4)

Rheumatic Diseases (Phase 4)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9